Clinical Trial: A Phase III Clinical Study to Evaluate the Efficacy and Safety of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets in Patients With Hyperprolactinemia

U.S., Aug. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07124221) titled 'A Phase III Clinical Study to Evaluate the Efficacy and Safety of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets in Patients With Hyperprolactinemia' on Aug. 03.

Brief Summary: A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia

Study Start Date: Aug. 30

Study Type: INTERVENTIONAL

Condition: Hyperprolactinemia

Intervention: DRUG: Cabergoline tablets

Cabergoline tablets will be administered for 14 weeks.The allowed dose range is from 0.25 mg (1 tablet) QW to 1mg (4 tablets) QW. Dosage adjustments are mad...